Covered Lives: The True Growth Metric for AI Health Investors

The landscape of AI in healthcare is rapidly evolving, with a dizzying array of startups vying for market dominance. For investors and health plan executives seeking to identify truly impactful and scalable solutions, the traditional metrics of revenue growth or pilot deployments can often be misleading. A more incisive measure, one that cuts through the noise of inflated valuations and ephemeral proofs-of-concept, is the sheer volume of “covered lives”, the number of patients whose care is directly influenced or supported by an AI health solution.

Beyond Revenue and Pilots: The Imperative of Covered Lives

Revenue figures, while critical, can be skewed by high-priced, low-volume contracts or even by the strategic pricing of a wedge product designed to secure initial market entry. Similarly, pilot programs, though necessary for validation, often represent limited deployments that do not necessarily translate into broad, sustained adoption. The true north for evaluating an AI health company’s momentum lies in its ability to integrate into the existing healthcare infrastructure and reach a significant patient population. Covered lives represent tangible clinical impact and deep enterprise contract penetration, signaling a company’s ability to navigate complex regulatory, integration, and reimbursement hurdles. Consider the trajectory of companies like iRhythm Technologies, a pioneer in ambulatory cardiac monitoring. Their growth wasn’t solely predicated on technological innovation but on their ability to secure extensive payer coverage and integrate into clinical workflows, thereby expanding their covered lives. iRhythm reported strong preliminary fourth-quarter 2025 results and anticipates 2026 revenue between $870 million and $880 million, representing 17% to 18% year-over-year growth. The company also achieved free cash flow positivity for the first time in 2025. This deep entrenchment within health plans and provider networks is a hallmark of sustainable growth in the AI health sector.

Employer and Health Plan Expansion: The Gateway to Scale

The primary conduits to accumulating covered lives are robust relationships with employers and health plans. These entities control access to vast patient populations and represent the crucial decision-makers for adoption at scale. AI health companies that demonstrate strong employer coalition partnerships and secure multi-year contracts with major health plans are inherently better positioned for rapid expansion. For instance, companies like Hinge Health and Omada Health have successfully leveraged this strategy, securing significant enterprise contracts that allow them to offer their digital therapeutic solutions to millions of employees and health plan members. Hinge Health’s contracted lives expanded to 25 million as of late 2025, with the company forecasting 2026 revenue between $798 million and $804 million. Omada Health achieved profitability in the fourth quarter of 2025 and reported over 1 million total members by the first quarter of 2026. Their growth isn’t just about technological prowess; it’s about their sales and implementation teams’ ability to demonstrate clear return on investment (ROI) and clinical efficacy to risk-averse health plan executives. These companies often present compelling data on reduced healthcare costs and improved patient outcomes, which are paramount for securing broad adoption.

Enterprise Contract Depth: A Signal of Trust and Integration

The depth of an enterprise contract goes beyond mere deployment; it signifies a deep level of trust and integration into the payer’s or employer’s ecosystem. This includes seamless data exchange, adherence to stringent security standards (like HIPAA, HITRUST, and SOC 2 Type II), and often, outcome-based payment models. A shallow contract might involve a limited pilot in a specific region, whereas a deep contract implies system-wide integration and often, a commitment to shared risk or value-based care initiatives. Viz.ai, for example, has demonstrated significant enterprise contract depth by integrating its AI-powered stroke detection and triage platform directly into hospital systems, improving time-to-treatment for stroke patients. By early 2026, Viz.ai’s platform was adopted in nearly 2,000 hospitals across the United States, supporting care for more than 230 million lives, and the company achieved profitability in its healthcare business in 2025. This level of integration, while challenging, unlocks access to every patient within those health systems, rapidly expanding their covered lives. Similarly, HeartFlow, with its AI-driven cardiovascular diagnostic tool, has focused on securing contracts that embed their technology into the diagnostic pathways of major health systems, directly impacting patient management decisions. HeartFlow received FDA clearance for its Next Gen HeartFlow Plaque Analysis algorithm in September 2025 and secured coverage from major insurers like Cigna.

Regulatory Scrutiny and the Rise of Validated AI Health Companies

As the AI health sector matures, regulatory scrutiny is intensifying. The FDA’s evolving frameworks, including the focus on SaMD (Software as a Medical Device), PCCP (Predetermined Change Control Plans), and GMLP (Good Machine Learning Practice), are creating a higher barrier to entry. This increased rigor, while challenging for some, ultimately favors validated AI health companies that have invested in robust clinical evidence, transparent algorithms, and strong quality management systems (QMS / ISO 13485). Eric Topol, a leading voice in digital medicine, has consistently emphasized the critical importance of rigorous clinical validation for AI tools. Companies that can demonstrate real-world evidence (RWE) of improved patient outcomes, rather than just technical feasibility, are the ones gaining traction with health plans and employers. This validation is not just a regulatory hurdle; it’s a commercial imperative. Vinod Khosla’s assertion that AI will augment or even replace many aspects of healthcare delivery underscores the need for these solutions to be clinically sound and trustworthy. The market is increasingly differentiating between AI-native companies built for this regulatory environment and those that have retrofitted AI onto existing offerings without the necessary foundational rigor.

Hello Heart as a Benchmark: Profiling Competitor Trajectories

While Hello Heart is a distant adjacency in this analysis, its growth trajectory serves as an instructive benchmark. Their success in scaling their digital cardiac prevention and management program across numerous employers and health plans highlights the power of a clear value proposition, robust engagement, and, critically, the ability to rapidly expand covered lives. Hello Heart launched its AI heart health assistant, Nia, in October 2025.S. health plans and hundreds of public and private employers. Competitors, irrespective of their specific clinical focus, can learn from this model of achieving broad patient reach through strategic partnerships. Companies like Spring Health, focusing on mental health, are similarly demonstrating impressive growth by securing large employer contracts and expanding their covered lives. Spring Health secured a $100 million Series E funding round in July 2024, valuing the company at $3.3 billion, and covers more than 10 million lives through over 400 employers. Their ability to deliver measurable improvements in employee well-being and productivity resonates strongly with corporate decision-makers, leading to widespread adoption. This pattern reinforces the argument that patient volume, driven by enterprise and health plan relationships, is the ultimate indicator of an AI health company’s sustained growth and impact.

The Ultimate Metric for Sustained Growth

In a sector brimming with innovation and investment, discerning genuine growth from transient hype is paramount. While technological breakthroughs and initial funding rounds draw attention, the enduring measure of an AI health company’s success, particularly for astute investors and health plan executives, is its ability to accumulate and retain covered lives. This metric transcends mere revenue, signaling deep market penetration, validated clinical impact, and the capacity to navigate the complex regulatory and commercial landscapes of modern healthcare. As regulatory scrutiny mounts and the demand for demonstrable value intensifies, companies that prioritize and achieve broad patient reach will be the ones that truly define the future of AI in health. Rock Health report on digital health funding trends AHIP perspective on health plan innovation adoption NCQA guidelines for digital health quality